Immunogenicity of biologic agents: A new concern for the practicing rheumatologist?

Current Rheumatology Reports

Volumn 9, Issue 4, 2007, Pages 265-267

  Haraoui, Boulos ^a   Pelletier, Jean Pierre ^b   Martel Pelletier, Johanne ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; RITUXIMAB;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; MEDICAL PRACTICE; MEDICAL SPECIALIST; MONOTHERAPY; NOTE; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

EID: 34547869629     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0042-x     Document Type: Note

References (6)

1. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
2. Haraoui B, Cameron L, Ouellet M, et al.: Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006, 33:31-36.
3. Weiner LM: Fully human therapeutic monoclonal antibodies. J Immunother 2006, 29:1-9.
4. Abbott Laboratories: Humira® (adalimumab) prescribing information. Available at http://www.rxabbott.com/pdf/humira.pdf. Accessed on May 14, 2007.
5. Cohen SB, Greenwald M, Dougados M, et al.: Efficacy and safety of Rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF alpha therapies (REFLEX Study) [abstract]. Arthritis Rheum 2005, 52:S677.
6. Klareskog L, Wajdula J, Baker P, et al.: Low and transient auto and anti-etanercept antibody formation has no measurable impact on clinical outcomes during 5 years of etanercept treatment in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2006, 65:325.